Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO
Kurs
+4,76%
Likviditet
0,02 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-25 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-12 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-13 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2025-05-14 | - | Årsstämma |
| 2025-05-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2025-01-20 | - | Extra Bolagsstämma 2025 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-14 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-05 | - | Extra Bolagsstämma 2024 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-12-20 | - | Extra Bolagsstämma 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Årsstämma |
| 2023-05-16 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2023-05-08 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2022-05-13 | - | Årsstämma |
| 2022-05-13 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-08 | - | Extra Bolagsstämma 2022 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-12-19 | - | Extra Bolagsstämma 2019 |
| 2019-11-05 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-13 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-11-20 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-07-25 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | X-dag ordinarie utdelning SIMRIS B 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-21 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-22 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-22 | - | Bokslutskommuniké 2016 |
| 2016-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-21 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Handel & varor |
| Industri | Dagligvaror |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective immediately.
Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry.
“Daniel Kubitza brings the necessary expertise needed to advance Simris and maximize our technology platform’s potential,” said Jonathan Royce, Board Chairperson at Simris Group.
During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
“We thank Alexis for her dedication and hard work. With the recent positive result from our ongoing preclinical study with Nuvisan, we reached an important milestone and will now embark on an accelerated growth strategy,” Royce concluded.
Contact Details:
Jonathan Royce
Chairman of Simris Group AB
Email: jonathan.royce@simris.com
Mobile: +46 (0) 70-143 41 43
www.simrisgroup.com
About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.
This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-10 08:30 CET.